View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 1, 2020

Eli Lilly launches world’s first clinical trial of antibody-based drug for Covid-19

By Allie Nawrat

Eli Lilly has initiated a Phase I study of an antibody-based drug, LY-CoV555, against Covid-19. This drug candidate was identified and developed as part of Lilly ‘s collaboration with Vancouver-based AbCellera signed in early May.

LY-CoV555 is an IgG1 monoclonal antibody, which targets the spike protein of SARS-CoV-2, the virus which causes Covid-19.

This randomised, placebo-controlled Phase I study aims to find out if LY-CoV555 is safe and tolerable in patients hospitalised with Covid-19. Results of this study are expected in late June, and then Lilly hopes it can quickly progress into a Phase II study of non-hospitalised Covid-19 patients.

Lilly chief scientific officer Daniel Skovronsky said: “We are privileged to help usher in this new era of drug development with the first potential new medicine specifically designed to attack the virus.

“Antibody therapies, such as LY-CoV555, may have potential for both prevention and treatment of COVID-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology